Germanium
carboxyethyl germanium
sesquioxide (Ge-132)
Here is a table of scientific studies which include
references to the organic substance called carboxyethyl germanium sesquioxide. This
substance was "discovered" and then synthesized by Dr. Kazuhiko Asai, who lived
in Japan many years ago. He wrote THE book, entitled "Miracle Cure Organic
Germanium," published in English by Japan Publications, Inc., copyrighted in 1980,
LCCC No. 79-91512, ISBN: 0-57040-474-3.
Karl's book was published by Life Extension Educational
Service in 1987, Second Edition, (now out of print).
The table below contains the title of the 39 various
scientific studies as well as a link to that study on this page.
You'll probably find that this is the only source of
scientific information about germanium available on the Internet.
Keep in mind that the ONLY form of germanium for which any
anti-cancer claims are made is, technically, germanium carboxyethyl sesquioxide.
I have included studies, below, on "germanium oxide" which is the most common
form of germanium. Germanium oxide is not very toxic -- it takes a dose of about 2
pounds to kill a mouse! But, the FDA has banned the importation of carboxyethyl
germanium sesquioxide into the US, probably instigating "studies" which would
show that "germanium" (actually germanium oxide) caused cancer. These
would be spurious references to criticize the true form of germanium which Dr. Asai
developed and researched in Japan.
| Number |
Official Title of the Study |
Comments |
| ...1... |
Mutagenicity, carcinogenicity and
teratogenicity of germanium compounds. |
"Germanium is not carcinogenic and even appears to inhibit cancer
development and, in the form of the organic germanium compound, spirogermanium,
to destroy cancer cells." |
| ...2... |
Hazard assessment of germanium supplements. |
Here is one of those fraudulent "studies" actually done by the
US Government, claiming toxicity for "germanium." |
| ...3... |
Effects of germanium oxide and other chemical
compounds on phenylmercury acetate-induced
genotoxicity in cultured human lymphocytes. |
Another study showing "dangers." Note the reference to
"germanium oxide" -- not the form recommended by Dr. Asai or sold by Vibrant
Life |
| ...4... |
Multidisciplinary treatment of head and neck
cancer using BCG, OK-432, and GE-132 as
biologic response modifiers. |
|
| ...5... |
Germanium intoxication with sensory ataxia. |
Another study on "inorganic germanium" -- which is NOT the one
you want. |
| ...6... |
Applications of a self-collimating BGO
detector system to radiological emergency response. |
|
| ...7... |
Germanium-induced nephropathy: report of two
cases and review of the literature. |
Another study of "germanium oxide." Germanium oxide can be
hidden, with vitamin C, and sold as "germanium sesquioxide" as a fraud. |
| ...8... |
Inhibitory effects of Ge-132 (carboxyethyl
germanium sesquioxide) derivatives on
enkephalin-degrading enzymes. |
|
| ...9... |
Phase I trial of spirogermanium given by
infusion in a multiple-dose schedule. |
|
| ..10... |
Phase II study of spirogermanium in
advanced ovarian malignancy. |
|
| ..11... |
Phase I clinical trial of spirogermanium. |
|
| ..12... |
Therapeutic effects of organic germanium. |
"Germanium is present in all living plant and animal matter in
micro-trace quantities. Its therapeutic attributes include immuno-enhancement, oxygen
enrichment, free radical scavenging, analgesia and heavy metal detoxification.
Toxicological studies document Germanium's rapid absorption and elimination from the body,
and its safety. Clinical trials and use in private practices for more than a decade have
demonstrated Germanium's efficacy in treating a wide range of serious afflictions,
including cancer, arthritis and senile osteoporosis. Germanium's anti-viral and
immunological properties, including the induction of interferon, macrophages, T-suppressor
cells and augmentation of natural killer cell activity, suggest its possible efficacy in
treating and/or preventing AIDS. " |
| ..13... |
Phase II study of N-methylformamide,
spirogermanium, and 4-demethoxydaunorubicin
in the treatment of non-small cell lung cancer
(EST 3583): an Eastern Cooperative Oncology
Group study |
|
| ..14... |
Tubulointerstitial nephropathy persisting
20 months after discontinuation of chronic
intake of germanium lactate citrate. |
|
| ..15... |
Abuse of germanium associated with
fatal lactic acidosis. |
Another study done with inorganic germanium -- a fraud. |
| ..16... |
Inhibition by germanium oxide of the mutagenicity
of cadmium chloride in various genotoxicity assays. |
|
| ..17... |
Effects of proxigermanium on interferon production
and 2',5'-oligoadenylate synthetase activity in the
lung of influenza virus-infected mice and in
virus-infected human peripheral blood mononuclear
cell cultures. |
|
| ..18... |
Germanium myopathy: clinical and experimental pathological studies. |
Another misleading study |
| ..19... |
Renal failure caused by long-term use of a germanium
preparation as an elixir. |
Another study of "inorganic" germanium. These dangerous
forms were deliberately spread in Japan, to cause death, so that the FDA could then claim
that ALL germanium was deadly, and thus ban import of this cancer-fighting agent. |
| ..20... |
Identification of synergistic combinations of spirogermanium with
5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro. |
| Menu
Choice #20 |
| ..21... |
A Phase I trial of spirogermanium administered
on a continuous infusion schedule. |
|
| ..22... |
Nephrotoxicity of germanium compounds: report
of a case and review of the literature |
|
| ..23... |
Spirogermanium: a new investigational drug of
novel structure and lack of bone marrow toxicity. |
|
| ..24... |
Phase I study of spirogermanium given daily. |
|
| ..25... |
Nephrotoxicity and neurotoxicity in humans from
organogermanium compounds and germanium dioxide. |
|
| ..26... |
Identification of 241Am in the axillary lymph nodes
with an intrinsic germanium detector. |
|
| ..27... |
Performance of an array of large-volume germanium
detectors for whole-body counting. |
|
| ..28... |
Germanium poisoning: clinical symptoms and renal
damage caused by long-term intake of germanium. |
|
| ..29... |
Nephrotoxicity in humans by the ultratrace element
germanium. |
|
| ..30... |
Cytotoxic effects and biological activity of
2-aza-8-germanspiro[4,5]-decane-2-propanamine-
8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro. |
|
| ..31... |
Determination of germanium and some other elements in hair, nail, and
toenail from persons exposed and unexposed to germanium. |
|
| ..32... |
Rotating laminar emission camera with GE-detector: an analysis. |
|
| ..33... |
Rotating laminar emission camera with GE-detector: experimental results. |
|
| ..34... |
Rotating laminar emission camera with GE-detector: experimental results. |
|
| ..35... |
A phase II study of spirogermanium in advanced human malignancy. |
|
| ..36... |
Accumulation of germanium in the tissues of a long-term user of germanium
preparation died of acute renal failure. |
|
| ..37... |
A phase II study of spirogermanium as second line therapy in patients with
poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study. |
|
| ..38... |
A phase II study of spirogermanium in patients with metastatic malignant
melanoma. An NCI Canada Clinical Trials Group Study. |
The required dose for treating cancer with the real germanium is about
2,000 mg per day. This study does not show how much was used -- typically these
fraudulent studies use a low dose or a different substance. |
| ..39... |
Germanium dioxide-induced nephropathy: a new type of renal disease. |
|
MEDLINE #1
Return To Top Of Menu
- Title
- Mutagenicity, carcinogenicity and teratogenicity of germanium compounds.
- Author
- Gerber GB; Léonard A
- Address
- Teratogenicity and Mutagenicity Unit, Catholic University of Louvain, Brussels, Belgium.
- Source
- Mutat Res, 1997 Dec, 387:3, 141-6
- Abstract
- The metalloid germanium has found widespread application in electronics, nuclear
sciences and in medicine. General toxicity of germanium is low, except for the
tetrahydride germane, and few observations on toxicity of germanium in man exist.
Germanium is not carcinogenic and even appears to inhibit cancer development and, in the
form of
- MeSH Heading
- (Major)
- Carcinogens|*TO; Germanium|CH/ME/*TO; Mutagens|*TO
- MeSH Heading
- Animal; Female; Human; Pregnancy
-
- The total dose of ingested germanium (as dioxide, carboxyethyl germanium sesquioxide,
germanium-lactate-citrate, or unspecified forms) varied from 15 to over 300 g; the
exposure duration varied from 2 to 36 months. In laboratory animals, elevated germanium in
tissues and impaired kidney and liver function were observed in a life-time drinking water
(5 ppm germanium) study. Other toxicities associated with ingested germanium products in
human cases were also demonstrated in animal studies with germanium dioxide and sometimes
other germanium compounds. Based on the evidence of persistent renal toxicity associated
with germanium dioxide, the lack of conclusive findings of differential nephrotoxicity of
organic germanium compounds, and the possibility of contamination of the organic germanium
products with inorganic germanium, it is clear that germanium products present a potential
human health hazard.
- Language of Publication
- English
- Unique Identifier
- 97380534
- MeSH Heading (Major)
- Food, Fortified|*; Germanium|*AE/PD/TO; Kidney|*DE; Liver|*DE
- MeSH Heading
- Administration, Oral; Adolescence; Adult; Anemia|CI; Animal; Antimutagenic
Agents|AE/PD/TO; Antineoplastic Agents|AE/PD/TO; Child; Child, Preschool; Female; Human;
Kidney Failure|CI; Lethal Dose 50; Male; Middle Age; Muscle Weakness|CI; Neurons|DE;
Organometallic Compounds|AE/PD/TO; Risk Assessment
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW OF REPORTED CASES
- ISSN
- 0273-2300
- Country of Publication
- UNITED STATES
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0027-5107
- Country of Publication
- NETHERLANDS
Record 2 from database: MEDLINE
Return To Top Of Menu
- Title
- Hazard assessment of germanium supplements.
- Author
- Tao SH; Bolger PM
- Address
- Center for Food Safety and Applied Nutrition, Food and Drug Administration, Washington,
DC 20204, USA.
-
- Source
- Regul Toxicol Pharmacol, 1997 Jun, 25:3, 211-9
- Abstract
- Germanium-containing dietary supplements became popular in the 1970s in Japan and later
in other countries, as elixirs for certain diseases (e.g., cancer and AIDS). Germanium is
not an essential element. Its acute toxicity is low. However, at least 31 reported human
cases linked prolonged intake of germanium products with renal failure and even death.
Signs of kidney dysfunction, kidney tubular degeneration, and germanium accumulation were
observed. Other adverse effects were anemia, muscle weakness, and peripheral neuropathy.
Recovery of renal function is slow and incomplete even long after germanium intake was
stopped.
-
Record 3 from database: MEDLINE
Return To Top Of Menu
- Title
- Effects of germanium oxide and other chemical compounds on phenylmercury acetate-induced
genotoxicity in cultured human lymphocytes.
- Author
- Lee CH; Lin RH; Liu SH; Lin Shiau SY
- Address
- Department of Pharmacology, Chung Shang Medical and Dental College, Taichung, Taiwan.
- Source
- Environ Mol Mutagen, 1998, 31:2, 157-62
- Abstract
- Phenylmercury acetate (PMA), which not only causes an elevation of sister chromatid
exchanges (SCEs) but also induces high frequency of endoreduplication in human
lymphocytes, may be genotoxic to humans. The major aim of our study was to investigate the
effects of germanium oxide (GeO2), D-penicillamine (D-PA), dimercaprol (BAL), and
diltiazem (DTM) on PMA-induced genotoxicity as quantified by SCEs. All concentrations of
the four chemical compounds tested alone did not induce genotoxicity in cultured human
lymphocytes. However, GeO2 significantly inhibited PMA-induced genotoxicity in a
concentration-dependent manner. Similarly, D-PA at concentrations of 3 microM and 10
microM, and BAL at a concentration of 30 microM produced the antigenotoxic effects. In
addition, GeO2 (1.5 microM) significantly reversed an increase of endoreduplication
frequency caused by PMA. In a cell cycle kinetic study, GeO2 (0.5-5.0 microM) reversed the
inhibition of PMA on the proliferating rate index (PRI) of lymphocytes. On the contrary,
both D-PA and DTM at concentrations of 30-300 microM markedly potentiated PMA-induced
inhibition of PRI. These findings show that GeO2, D-PA and BAL could antagonize
PMA-induced genotoxicity, and GeO2 appears to be the most effective.
- Language of Publication
- English
- Unique Identifier
- 98205834
- MeSH Heading (Major)
- Antidotes|AD/*PD; Antimutagenic Agents|AD/*PD; Fungicides, Industrial|AI/PD/*TO;
Germanium|AD/*PD; Lymphocytes|CY/*DE; Phenylmercuric Acetate|AI/PD/*TO
- MeSH Heading
- Adult; Calcium Channel Blockers|AD/PD; Cells, Cultured; Diltiazem|AD/PD;
Dimercaprol|AD/PD; Dose-Response Relationship, Drug; Human; Male; Mitomycin C|PD/TO;
Mutagenesis|DE/GE; Nucleic Acid Synthesis Inhibitors|PD/TO; Penicillamine|AD/PD; Sister
Chromatid Exchange|DE/GE; Support, Non-U.S. Gov't; Support, U.S. Gov't, Non-P.H.S.
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0893-6692
- Country of Publication
- UNITED STATES
Record 4 from database: MEDLINE
Return To Top Of Menu
- Title
- Multidisciplinary treatment of head and neck cancer using BCG, OK-432, and GE-132 as
biologic response modifiers.
- Author
- Fukazawa H; Ohashi Y; Sekiyama S; Hoshi H; Abe M; Takahashi M; Sato T
- Address
- 2nd Department of Oral and Maxillofacial Surgery, Niigata University, School of
Dentistry, Japan.
- Source
- Head Neck, 1994 Jan, 16:1, 30-8
- Abstract
- Since 1979, we have performed multidisciplinary treatment using intensive immunotherapy
with biologic response modifiers (BRM) in combination with surgical treatment of oral
cancer. Chemotherapy and radiotherapy were also included as part of the therapy. A
historic control study was performed. Adjuvant therapy was administered by standardized
methods, and the distribution of patients at various stages was similar between groups.
The immunotherapy group showed a shorter treatment period, lower rates of recurrence,
metastases, and side effects, greater histologic effects at the end of the first
treatment, and a higher survival rate than the nonimmunotherapy group. Immunologically,
immunotherapy tended to promote positive immune reactions and inhibit negative immune
reactions.
- Language of Publication
- English
- Unique Identifier
- 94171557
- MeSH Heading (Major)
- Antineoplastic Agents|AD/*TU; Biological Response Modifiers|AD/*TU; BCG Vaccine|AD/*TU;
Carcinoma|PA/RA/SC/SU/*TH; Germanium|AD/*TU; Head and Neck Neoplasms|PA/RT/SU/*TH;
Interferon Inducers|AD/*TU; Organometallic Compounds|AD/*TU; Picibanil|AD/*TU
- MeSH Heading
- alpha-Macroglobulins|AN; Antineoplastic Agents, Combined|AD/TU; Combined Modality
Therapy; Female; Human; Interferons|BI; Male; Middle Age; Neoplasm Proteins|AN; Neoplasm
Recurrence, Local; Prognosis; Survival Rate; T-Lymphocytes|PA; Tumor Necrosis Factor|AN
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 1043-3074
- Country of Publication
- UNITED STATES
Record 5 from database: MEDLINE
Return To Top Of Menu
- Title
- Germanium intoxication with sensory ataxia.
- Author
- Asaka T; Nitta E; Makifuchi T; Shibazaki Y; Kitamura Y; Ohara H; Matsushita K; Takamori
M; Takahashi Y; Genda A
- Address
- Department of Neurology, Kanazawa University School of Medicine, Japan.
- Source
- J Neurol Sci, 1995 Jun, 130:2, 220-3
- Abstract
- Sensory ataxia in inorganic germanium intoxication is rare. A 63-year-old housewife had
taken inorganic germanium preparations at a dosage of 36 mg a day for about 6 years (total
dose about 80 g). She subsequently developed difficulty in writing and gait disturbance
with peripheral neuropathy and renal involvement. Germanium, which is not usually detected
in the non-germanium user, was accumulated in her hair and nails, permitting a diagnosis
of inorganic germanium intoxication. The peripheral neuropathy and renal injury were not
reversible after discontinuing the preparation. Pneumonia and sepsis then supervened and
the patient died. Autopsy findings showed degeneration and loss of the dorsal root
ganglion cells and degeneration of the dorsal column of the spinal cord. Two previously
reported cases presented with ataxia. These patients took germanium for long periods
and/or large quantities like our case. It was supposed that sensory ataxia was induced by
chronic and dose dependent toxicity of inorganic germanium.
- Language of Publication
- English
- Unique Identifier
- 96172603
- MeSH Heading (Major)
- Ataxia|*CI/PA/PP; Germanium|*PO
- MeSH Heading
- Aged; Brain|PA; Case Report; Female; Ganglia|PA; Human; Kidney Diseases|CI/PA; Magnetic
Resonance Imaging; Motor Neurons|DE; Nerve Degeneration|DE; Neural Conduction|DE; Spinal
Cord|PA
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0022-510X
- Country of Publication
- NETHERLANDS
Record 6 from database: MEDLINE
Return To Top Of Menu
- Title
- Applications of a self-collimating BGO detector system to radiological emergency
response.
- Author
- Pernick A; Orion I; Ilzycer D; Zafrir H
- Address
- Soreq Nuclear Research Center, Yavne, Israel.
- Source
- Health Phys, 1997 Jan, 72:1, 136-40
- Abstract
- The capability of a recently developed BGO detector system featuring a
"self-collimating" structure to locate a point source was established by Monte
Carlo simulations and by laboratory scale experiments. The detector system's capability to
determine the direction of a nuclear plume resulting from a PWR1 or PWR2 type accident in
stable atmospheric conditions by airborne monitoring of the 2.4 MeV photons emitted by
88Kr was established by Monte Carlo simulations.
- Language of Publication
- English
- Unique Identifier
- 97128245
- MeSH Heading (Major)
- Accidents, Radiation|*; Bismuth|*AN; Germanium|*AN; Radiation Monitoring|*MT
- MeSH Heading
- Cesium Radioisotopes; Human; Krypton Radioisotopes; Monte Carlo Method; Radiation
Protection
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0017-9078
- Country of Publication
- UNITED STATES
Record 7 from database: MEDLINE
Return To Top Of Menu
- Title
- Germanium-induced nephropathy: report of two cases and review of the literature.
- Author
- Matsusaka T; Fujii M; Nakano T; Terai T; Kurata A; Imaizumi M; Abe H
- Address
- Division of Cardiovascular and Kidney Disease, Osaka National Hospital, Japan.
- Source
- Clin Nephrol, 1988 Dec, 30:6, 341-5
- Abstract
- We report two cases of renal failure following long-term ingestion of germanium dioxide
(GeO2) and comment on eight other cases reported in Japan. Ge-induced nephropathy is
characterized by insidious onset of renal failure without proteinuria or hematuria after
oral intake of Ge-containing compounds for more than several months, and by degeneration
of renal tubular cells with minor glomerular abnormality in histology. When patients
ceased to ingest Ge compounds, renal function gradually recovered but never returned to
the normal range. Serious extrarenal complication can contribute to an unfavorable
prognosis.
- Language of Publication
- English
- Unique Identifier
- 89209410
- MeSH Heading (Major)
- Germanium|*AE/AN/PK; Kidney Failure, Acute|*CI/PA
- MeSH Heading
- Adult; Case Report; Female; Heart Hypertrophy|ET; Human; Kidney|PA; Male; Middle Age;
Myocardium|PA; Time Factors; Tissue Distribution
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW OF REPORTED CASES
- ISSN
- 0301-0430
- Country of Publication
- GERMANY, WEST
- CAS Registry/EC Number
- 1310-53-8 (germanium oxide); 7440-56-4 (Germanium)
Record 8 from database: MEDLINE
Return To Top Of Menu
- Title
- Inhibitory effects of Ge-132 (carboxyethyl germanium sesquioxide) derivatives on
enkephalin-degrading enzymes.
- Author
- Komuro T; Kakimoto N; Katayama T; Hazato T
- Address
-
- Source
- Biotechnol Appl Biochem, 1986 Oct, 8:5, 379-86
- Abstract
- Twenty-eight species of carboxyethyl germanium sesquioxide (Ge-132) derivatives were
examined for their inhibitory effects on enkephalin-degrading enzymes that were purified
from monkey brain, the longitudinal muscle layer of bovine small intestine, and human
cerebrospinal fluid (CSF). A series of the sulfurized Ge-132 derivatives showed strong
inhibition of these purified enzymes. The most effective ones were Ge-014 and Ge-107,
which showed IC50 values of 60 and 100 micrograms/ml, respectively, for
dipeptidylcarboxypeptidase from the longitudinal muscle layer. They also exhibited
inhibitory activity against aminopeptidase from human CSF, the IC50 values being 450 and
440 micrograms/ml, respectively. Furthermore, these compounds showed inhibition of
dipeptidylaminopeptidase from monkey brain and the longitudinal muscle layer of bovine
small intestine. These compounds are expected to have analgesic effects due to their
inhibition of the degradation of endogenous opioid peptides.
- Language of Publication
- English
- Unique Identifier
- 87026253
- MeSH Heading (Major)
- Aminopeptidases|*AI; Carboxypeptidases|*AI; Dipeptidyl Peptidases|*AI; Germanium|*PD;
Organometallic Compounds|*PD; Protease Inhibitors|*
- MeSH Heading
- Analgesics|PD; Animal; Brain|EN; Cattle; Comparative Study; Enkephalins|ME;
Guanidines|PD; Haplorhini; Human; Intestine, Small|EN
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0885-4513
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 3.4. (Carboxypeptidases); EC 3.4.- (Peptide Peptidohydrolases); EC 3.4.11.
(Aminopeptidases); EC 3.4.14. (Dipeptidyl Peptidases); EC 3.4.15.- (dipeptidyl
carboxypeptidase); 0 (Analgesics); 0 (Enkephalins); 0 (Guanidines); 0 (Organometallic
Compounds); 0 (Protease Inhibitors); 12758-40-6 (proxigermanium); 7440-56-4 (Germanium);
85713-14-0 (arphamenine A); 88465-81-0 (arphamenine B)
Record 9 from database: MEDLINE
Return To Top Of Menu
- Title
- Phase I trial of spirogermanium given by infusion in a multiple-dose schedule.
- Author
- Budman DR; Schulman P; Vinciguerra V; Degnan TJ
- Address
-
- Source
- Cancer Treat Rep, 1982 Jan, 66:1, 173-5
- Abstract
- In a phase I study of spirogermanium, a new azaspiran-germanium compound, 28 patients
were given a multiple-dose schedule. When infused over 1 hour, the maximum tolerated
single dose of this agent was greater than 120 mg/m2 but significant chronic neurologic
toxicity occurred after 1-2 weeks of treatment. Patients with a poor performance status
(PS) were the most likely to manifest toxic reactions. Suggested phage II dose levels for
infusion treatment with spirogermanium are 120 mg/m2 for patients with a PS of 0-2 and 80
mg/m2 for patients with a PS of 3.
- Language of Publication
- English
- Unique Identifier
- 82070170
- MeSH Heading (Major)
- Antineoplastic Agents|*AD/AE; Germanium|*AD/AE; Spiro Compounds|*AD/AE
- MeSH Heading
- Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Human; Kidney
Diseases|CI; Male; Middle Age
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0361-5960
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4
(Germanium)
Record 10 from database: MEDLINE
Return To Top Of Menu
- Title
- Phase II study of spirogermanium in advanced ovarian malignancy.
- Author
- Tropé C; Mattsson W; Gynning I; Johnsson JE; Sigurdsson K; Orbert B
- Address
-
- Source
- Cancer Treat Rep, 1981 Jan-Feb, 65:1-2, 119-20
- Abstract
- In the present phase II trial 18 heavily pretreated patients with advanced ovarian
malignancy were treated with spirogermanium, 11 im and seven iv. Objective responses
(partial remission) were obtained in two (11%) of the 18 patients, with a remission
duration of 5 and 23 + months, respectively. An additional four (22%) patients had stable
disease. Each of these six patients had a better quality of life. There were few side
effects. Myelosuppression, nausea, or other gastrointestinal side effects did not occur.
The present investigation shows that spirogermanium is useful as a palliative
chemotherapeutic agent in patients with advanced ovarian malignancy.
- Language of Publication
- English
- Unique Identifier
- 81186146
- MeSH Heading (Major)
- Adenocarcinoma, Mucinous|*DT; Antineoplastic Agents|*TU; Cystadenocarcinoma|*DT;
Germanium|*TU; Ovarian Neoplasms|*DT; Spiro Compounds|*TU
- MeSH Heading
- Drug Evaluation; Female; Human; Neoplasm Recurrence, Local; Remission, Spontaneous
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0361-5960
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4
(Germanium)
Record 11 from database: MEDLINE
Return To Top Of Menu
- Title
- Phase I clinical trial of spirogermanium.
- Author
- Schein PS; Slavik M; Smythe T; Hoth D; Smith F; Macdonald JS; Woolley PV
- Address
-
- Source
- Cancer Treat Rep, 1980 Oct-Nov, 64:10-11, 1051-6
- Abstract
- Spirogermanium is a new azaspirane antitumor agent, with the metal germanium substituted
for a one-carbon moiety in the ring structure. This drug inhibits DNA and RNA synthesis in
HeLa cells, is cytotoxic in vitro, and has curative in vivo antitumor activity against the
ascitic Walker 256 carcinosarcoma in rats. No hematologic toxicity was recorded during the
preclinical toxicologic evaluation. The principal clinical toxic effects observed in this
phase I trial were neurologic, manifested as lethargy, dizziness, and ataxia, while a
grand mal seizure was produced after an accidental overdose. There was no evidence of
hematologic, renal, or hepatic toxicity. A partial response was achieved in a patient with
a well-differentiated lymphocytic lymphoma. We recommend that phase II trials be conducted
with a twice or thrice weekly dose of 50-80 mg/m2, administered in a 30-minute iv
infusion.
- Language of Publication
- English
- Unique Identifier
- 81111935
- MeSH Heading (Major)
- Antineoplastic Agents|*TO/TU; Germanium|*TO/TU; Spiro Compounds|*TO/TU
- MeSH Heading
- Adult; Aged; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hela
Cells|DE/ME; Human; Male; Middle Age; Neoplasms|DT; Nervous System Diseases|CI
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0361-5960
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4
(Germanium)
Record 12 from database: MEDLINE
Return To Top Of Menu
- Title
- Therapeutic effects of organic germanium.
- Author
- Goodman S
- Address
- International Inst. of Symbiotic Studies, Brighton, Sussex, U.K.
- Source
- Med Hypotheses, 1988 Jul, 26:3, 207-15
- Abstract
- Germanium is present in all living plant and animal matter in micro-trace quantities.
Its therapeutic attributes include immuno-enhancement, oxygen enrichment, free radical
scavenging, analgesia and heavy metal detoxification. Toxicological studies document
Germanium's rapid absorption and elimination from the body, and its safety. Clinical
trials and use in private practices for more than a decade have demonstrated Germanium's
efficacy in treating a wide range of serious afflictions, including cancer, arthritis and
senile osteoporosis. Germanium's anti-viral and immunological properties, including the
induction of interferon, macrophages, T-suppressor cells and augmentation of natural
killer cell activity, suggest its possible efficacy in treating and/or preventing AIDS.
- Language of Publication
- English
- Unique Identifier
- 88301938
- MeSH Heading (Major)
- Germanium|TO/*TU
- MeSH Heading
- Acquired Immunodeficiency Syndrome|DT; Animal; Antineoplastic Agents|TU; Arthritis|DT;
Clinical Trials; Female; Human; Leukemia, Experimental|DT; Lung Neoplasms|DT;
Lymphoproliferative Disorders|DT; Malaria|DT; Organometallic Compounds|TU;
Osteoporosis|DT; Ovarian Neoplasms|DT; Spiro Compounds|TU
- Publication Type
- CLINICAL TRIAL; JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0306-9877
- Country of Publication
- ENGLAND
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Organometallic Compounds); 0 (Spiro Compounds); 41992-23-8
(spirogermanium); 7440-56-4 (Germanium)
Record 13 from database: MEDLINE
Return To Top Of Menu
- Title
- Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the
treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group
study.
- Author
- Ettinger DS; Finkelstein DM; Donehower RC; Chang AY; Green M; Blum R; Hahn RG;
Ruckdeschel JC
- Address
- Johns Hopkins Oncology Center, Baltimore, Maryland ff205.
- Source
- Med Pediatr Oncol, 1989, 17:3, 197-201
- Abstract
- One hundred forty-four patients with non-small cell lung cancer, the majority (72%) of
whom had received previous chemotherapy, were evaluable in this randomized phase II study
of N-methylformamide (N-MF), spirogermanium, and 4-demethoxydaunorubicin. There were two
partial responses, one each with spirogermanium and 4-demethoxydaunorubicin. There were
eight life-threatening complications (mostly hematologic) and two lethal complications
(N-MF, hematologic; 4-demethoxydaunorubicin, gastrointestinal). The overall survival
ranged from 9 days to 533 days with a median of 17.6 weeks. The following factors were
associated with poor survival: Poor initial performance status, prior weight loss,
presence of liver or subcutaneous metastases.
- Language of Publication
- English
- Unique Identifier
- 89313530
- MeSH Heading (Major)
- Antineoplastic Agents|AE/*TU; Carcinoma, Non-Small-Cell Lung|*DT; Formamides|AE/*TU;
Germanium|AE/*TU; Idarubicin|*TU; Lung Neoplasms|*DT; Organometallic Compounds|AE/*TU;
Spiro Compounds|AE/*TU
- MeSH Heading
- Aged; Drug Evaluation; Female; Human; Male; Middle Age; Prognosis; Random Allocation;
Remission Induction; Support, U.S. Gov't, P.H.S.
- Publication Type
- CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
- ISSN
- 0098-1532
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Formamides); 0 (Organometallic Compounds); 0 (Spiro
Compounds); 123-39-7 (methylformamide); 41992-23-8 (spirogermanium); 58957-92-9
(Idarubicin); 7440-56-4 (Germanium)
Record 14 from database: MEDLINE
Return To Top Of Menu
- Title
- Tubulointerstitial nephropathy persisting 20 months after discontinuation of chronic
intake of germanium lactate citrate.
- Author
- Hess B; Raisin J; Zimmermann A; Horber F; Bajo S; Wyttenbach A; Jaeger P
- Address
- Policlinic of Medicine, University Hospital, Berne, Switzerland.
- Source
- Am J Kidney Dis, 1993 May, 21:5, 548-52
- Abstract
- Two young human immunodeficiency virus (HIV)-infected patients, a 25-year-old woman and
a 26-year-old man, consumed large amounts of germanium lactate citrate 18% as an
"immunostimulant" for 9 months. The woman, who had stage II HIV infection,
developed severe renal dysfunction (creatinine clearance, 7 mL/min/1.73 m2) and slight
proteinuria (0.28 g/d) after ingesting 260 g germanium lactate citrate 18%. Hepatomegaly
with liver dysfunction (SGOT, 102 U/L; gamma-glutamyl transferase (GT), 159 U/L) and
lactic acidosis (plasma lactate, 7.3 mmol/L) developed simultaneously. Renal biopsy
revealed tubulointerstitial nephropathy with vacuolar cell degeneration and periodic
acid-Schiff-positive intracellular deposits mainly in distal tubules. Liver biopsy
disclosed severe hepatic steatosis; liver function tests returned to normal within 5
weeks. Since renal failure persisted for 2 years after ingestion of germanium (creatinine
clearance, 14 mL/min/1.73 m2; proteinuria, 0.84 g/d), a second renal biopsy was performed,
which showed marked but focal distal tubular atrophy and slight interstitial fibrosis. The
male patient, who had stage III HIV infection, had ingested the same compound; he
presented with a creatinine clearance of 43 mL/min/m2 and proteinuria of 0.36 g/d. Renal
biopsy disclosed tubulointerstitial changes similar to those found in the female patient.
After 9 months off germanium, creatinine clearance remained unchanged. Neutron activation
analysis of all biopsy specimens in both cases documented germanium concentrations 10 to
70 times normal in renal tissue and 140 times normal in liver tissue.
- Language of Publication
- English
- Unique Identifier
- 93256055
- MeSH Heading (Major)
- Germanium|AD/*AE; HIV Infections|*DT; Nephritis, Interstitial|*CI/PA
- MeSH Heading
- Adult; Case Report; Chronic Disease; Female; Human; Kidney Tubules|PA/UL; Male;
Microscopy, Electron; Time Factors
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0272-6386
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 7440-56-4 (Germanium)
Record 15 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Abuse of germanium associated with fatal lactic acidosis.
- Author
- Krapf R; Schaffner T; Iten PX
- Address
- Department of Medicine, Hospital of St. Gall, Switzerland.
- Source
- Nephron, 1992, 62:3, 351-6
- Abstract
- Germanium compounds are marketed as nonprescription drugs in Europe and are recommended
by the suppliers for AIDS and metastatic cancer disease. We observed a patient with
nonmetastatic breast cancer who died because of severe lactic acidosis (plasma lactate
concentration = 27 mmol/l) after ingestion of 25 g of elemental germanium over a 2-months
period. Renal failure and hepatotoxicity had newly developed during germanium intake.
Postmortem examination revealed severe hydropic vacuolation of tubule cells and the
presence of inclusion bodies predominantly in straight proximal tubule cells with normal
appearance of renal interstitium and glomeruli. The liver showed panlobular steatosis.
Urine, blood and tissue (kidney, liver, muscle, pancreas) levels of germanium were high.
Lactic acidosis may have been caused by the combined, germanium-induced renal and hepatic
failure (underutilization), but it remains to be seen whether germanium can affect lactate
production and/or metabolism directly.
- Language of Publication
- English
- Unique Identifier
- 93063655
- MeSH Heading (Major)
- Acidosis|*CI; Germanium|*PO; Lactates|*BL
- MeSH Heading
- Adult; Case Report; Female; Human; Kidney Failure, Acute|CI; Liver Diseases|CI;
Pancreatitis|CO
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0028-2766
- Country of Publication
- SWITZERLAND
- CAS Registry/EC Number
- 0 (Lactates); 50-21-5 (Lactic Acid); 7440-56-4 (Germanium)
Record 16 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Inhibition by germanium oxide of the mutagenicity of cadmium chloride in various
genotoxicity assays.
- Author
- Han C; Wu G; Yin Y; Shen M
- Address
- Department of Hygiene, Yanbian Medical College, Yanji City, Jilin Province, China.
- Source
- Food Chem Toxicol, 1992 Jun, 30:6, 521-4
- Abstract
- The effects of germanium oxide on the genotoxicity of cadmium chloride were
investigated. The incorporation of [3H]thymidine into testicular DNA was inhibited in mice
injected ip with 1.35, 1.80 or 2.70 mg cadmium chloride/kg body weight. Germanium oxide
(0.05 or 0.1 mg/kg body weight, sc) alone did not affect [3H]thymidine incorporation into
testicular DNA but 0.05 mg germanium oxide/kg antagonized the inhibitory effect of 1.35 mg
cadmium chloride/kg. However, combinations of the other doses of the two compounds did not
show statistically significant antagonistic effects. Cadmium chloride significantly
increased the frequencies of micronucleus formation in polychromatic erythrocytes, and of
chromosome aberrations in the bone marrow of mice treated with 0.7, 1.4 or 2.7 mg/kg body
weight, in a dose-related manner. These effects were inhibited by germanium oxide at doses
of 0.1 or 0.5 mg/kg body weight, although germanium oxide alone did not affect
micronucleus formation or the chromosome aberration rate. Cadmium chloride produced a
dose-related increase in the frequency of sister chromatid exchanges in cultured human
lymphocytes at concentrations of 5, 10 or 50 mumol. This effect was also inhibited by
germanium oxide (0.05 or 0.1 mumol), although germanium oxide alone had no effect. There
was a dose-related increase in the frequency of sperms with abnormal head morphologies
from mice treated with 0.6, 1.1 or 2.2 mg cadmium chloride/kg body weight and this too was
antagonized by the injection of germanium oxide (0.1 or 0.5 mg/kg body weight). Germanium
oxide alone did not affect the frequency of sperm-head abnormalities.
- Language of Publication
- English
- Unique Identifier
- 92363327
- MeSH Heading (Major)
- Antimutagenic Agents|*PD; Cadmium|*AI/TO; Chlorides|*AI/TO; Chromosomes|*DE; DNA|BI/*DE;
Germanium|*PD
- MeSH Heading
- Animal; Bone Marrow|CY/DE; Chromosome Aberrations; Dose-Response Relationship, Drug;
Human; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Micronucleus Tests; Sister
Chromatid Exchange|DE; Sperm Head|DE
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0278-6915
- Country of Publication
- ENGLAND
- CAS Registry/EC Number
- 0 (Antimutagenic Agents); 0 (Chlorides); 10108-64-2 (Cadmium Chloride); 1310-53-8
(germanium oxide); 7440-43-9 (Cadmium); 7440-56-4 (Germanium); 9007-49-2 (DNA)
Record 17 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Effects of proxigermanium on interferon production and 2',5'-oligoadenylate synthetase
activity in the lung of influenza virus-infected mice and in virus-infected human
peripheral blood mononuclear cell cultures.
- Author
- Ishiwata Y; Yokochi S; Suzuki E; Michishita H; Tashita A; Asano K; Mitani T; Kurono M
- Address
- Mie Laboratory, Sanwa Kagaku Kenkyusho Co. Ltd., Japan.
- Source
- Arzneimittelforschung, 1990 Aug, 40:8, 896-9
- Abstract
- Proxigermanium (SK-818) is a synthesized organic germanium compound having various
biological activities. The effects of proxigermanium on interferon (IFN) production in
mice infected with influenza virus and virus-infected human peripheral blood mononuclear
cells (hPBMC) were investigated. Proxigermanium alone did not induce IFN production in
normal mice or in hPBMC without viral infection. On the other hand, proxigermanium
enhanced alpha/beta IFN production in viral-infected mice and hPBMC. Since proxigermanium
is known to have antiviral activity in vivo but not in vitro, it is likely that the IFN
production augumenting activity of proxigermanium is involved in its antiviral activities.
- Language of Publication
- English
- Unique Identifier
- 91054674
- MeSH Heading (Major)
- Adjuvants, Immunologic|*PD; Germanium|*PD; Influenza|*ME; Interferons|*BI; Lung|*EN;
Neutrophils|DE/*EN; Organometallic Compounds|*PD; 2',5'-Oligoadenylate Synthetase|*ME
- MeSH Heading
- Animal; Cells, Cultured; Human; Indicators and Reagents; Influenza A Virus, Human; Mice;
Mice, Inbred BALB C
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0004-4172
- Country of Publication
- GERMANY
- CAS Registry/EC Number
- EC 2.7.7.- (2',5'-Oligoadenylate Synthetase); 0 (Adjuvants, Immunologic); 0 (Indicators
and Reagents); 0 (Organometallic Compounds); 12758-40-6 (proxigermanium); 7440-56-4
(Germanium); 9008-11-1 (Interferons)
Record 18 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Germanium myopathy: clinical and experimental pathological studies.
- Author
- Higuchi I; Izumo S; Kuriyama M; Suehara M; Nakagawa M; Fukunaga H; Osame M; Ohtsubo S;
Miyata K
- Address
- Third Department of Internal Medicine, Faculty of Medicine, Kagoshima University, Japan.
- Source
- Acta Neuropathol (Berl), 1989, 79:3, 300-4
- Abstract
- Pathological examinations were carried out on the skeletal muscle of a patient with
germanium intoxication. The prominent histochemical finding was vacuolar myopathy with
lipid excess, increased acid phosphatase activity and decreased cytochrome c oxidase
activity. Ultrastructural lesions revealed a mitochondrial abnormality, autophagic
vacuoles and accumulation of high electron-dense materials in deformed mitochondria and at
the periphery of lipid droplets. Furthermore, the toxic effect of germanium on skeletal
muscle was confirmed by the experimentally induced germanium myopathy, which showed
autophagic degeneration, decreased cytochrome c oxidase activity and a mitochondrial
abnormality with high electron-dense materials.
- Language of Publication
- English
- Unique Identifier
- 90118781
- MeSH Heading (Major)
- Germanium|*AE; Muscular Diseases|*CI/PA
- MeSH Heading
- Case Report; Child, Preschool; Human; Male; Muscles|UL
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0001-6322
- Country of Publication
- GERMANY, WEST
- CAS Registry/EC Number
- 7440-56-4 (Germanium)
Record 19 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Renal failure caused by long-term use of a germanium preparation as an elixir.
- Author
- Okada K; Okagawa K; Kawakami K; Kuroda Y; Morizumi K; Sato H; Morita H; Shimomura S;
Saito S
- Address
- Department of Pediatrics, School of Medicine, University of Tokushima, Japan.
- Source
- Clin Nephrol, 1989 Apr, 31:4, 219-24
- Abstract
- Two Japanese women and one Japanese man, who had been taking the same germanium
preparation, mainly containing inorganic germanium, as an elixir for health almost every
day at 90 mg of germanium per day for 6 to 20 months, suffered from chronic renal failure.
Histological examination of the kidney in one patient showed marked interstitial changes
with vacuolar degeneration of the renal tubules. High germanium concentrations were found
in hair and nails of the three patients, but no germanium was detected in hair or nails of
normal persons. These results suggest that long-term use of a germanium preparation at
high dosage can cause serious renal tubular damage and renal failure due to germanium
toxicity.
- Language of Publication
- English
- Unique Identifier
- 89230846
- MeSH Heading (Major)
- Germanium|AN/*PO/TU; Kidney Failure, Chronic|*CI/PA
- MeSH Heading
- Adult; Case Report; Female; Hepatitis B|TH; Human; Kidney|PA; Male
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0301-0430
- Country of Publication
- GERMANY, WEST
- CAS Registry/EC Number
- 7440-56-4 (Germanium)
Record 20 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Identification of synergistic combinations of spirogermanium with 5-fluorouracil or
cisplatin using a range of human tumour cell lines in vitro.
- Author
- Hill BT; Bellamy AS; Metcalfe S; Hepburn PJ; Masters JR; Whelan RD
- Address
-
- Source
- Invest New Drugs, 1984, 2:1, 29-33
- Abstract
- A series of continuous human tumour cell lines, derived from various tumour types, were
used to establish whether the combination of spirogermanium (SP) with other 'standard'
antitumour drugs proved superior to these as single agents in reducing cell survival in
vitro. A non-cytotoxic concentration of SP was selected and when combined with a range of
concentrations of cisplatin or 5-fluorouracil (5-FU), definite synergistic cell kill was
noted in all lines tested. In contrast, the combination of SP with various other antitumor
drugs, including adriamycin, methotrexate and the vinca alkaloids and with X-irradiation
did not enhance cytotoxicity. These pre-clinical in vitro studies suggest that benefit may
accrue from combining SP with either 5-FU or cisplatin and provide a basis for their
clinical evaluation in colo-rectal tumours or transitional cell cancer of the bladder,
respectively.
- Language of Publication
- English
- Unique Identifier
- 84288357
- MeSH Heading (Major)
- Antineoplastic Agents|*AD/PD; Antineoplastic Agents, Combined|*; Cisplatin|*AD/PD;
Colony-Forming Units Assay|*; Fluorouracil|*AD/PD; Germanium|*AD/PD; Spiro
Compounds|*AD/PD; Tumor Stem Cell Assay|*
- MeSH Heading
- Cell Line; Cell Survival|DE; Doxorubicin|PD; Drug Synergism; Human; Methotrexate|PD
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0167-6997
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Antineoplastic Agents, Combined); 0 (Spiro Compounds);
15663-27-1 (Cisplatin); 23214-92-8 (Doxorubicin); 41992-23-8 (spirogermanium); 51-21-8
(Fluorouracil); 59-05-2 (Methotrexate); 7440-56-4 (Germanium)
Record 21 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- A Phase I trial of spirogermanium administered on a continuous infusion schedule.
- Author
- Woolley PV; Ahlgren JD; Byrne PJ; Priego VM; Schein PS
- Address
-
- Source
- Invest New Drugs, 1984, 2:3, 305-9
- Abstract
- We have evaluated the toxicity of the antitumor agent spirogermanium on a schedule of
continuous intravenous administration for periods up to five days. The doses tested were
between 100 mg/m2/day and 500 mg/m2/day. Peripheral vein phlebitis occurred at all dose
levels and was not relieved by addition of hydrocortisone or heparin to the infusion. No
phlebitis occurred when the drug was administered through a central vein. The dose
limiting toxicity of spirogermanium was neurologic, notably tremors and mental confusion.
These problems became progressively more severe at doses above 250 mg/m2/day. There was no
discernible bone marrow, renal or hepatic toxicity. One patient developed reversible
interstitial pneumonitis. The recommended Phase II dose of spirogermanium is 200 mg/m2/day
for five days, with the possibility of escalation in selected patients. Because
spirogermanium is more toxic to tumor cells with prolonged exposure than with intermittent
exposure, this schedule could be considered for Phase II trials, particularly in diseases
thought to be especially sensitive such as ovarian and prostatic carcinoma or lymphomas.
- Language of Publication
- English
- Unique Identifier
- 85078935
- MeSH Heading (Major)
- Antineoplastic Agents|AD/*AE/BL; Germanium|AD/*AE/BL; Spiro Compounds|AD/*AE/BL
- MeSH Heading
- Adult; Aged; Drug Evaluation; Female; Human; Infusions, Parenteral; Male; Middle Age;
Neoplasms|DT; Nervous System|DE; Phlebitis|CI; Support, Non-U.S. Gov't
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0167-6997
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4
(Germanium)
Record 22 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Nephrotoxicity of germanium compounds: report of a case and review of the literature.
- Author
- Takeuchi A; Yoshizawa N; Oshima S; Kubota T; Oshikawa Y; Akashi Y; Oda T; Niwa H;
Imazeki N; Seno A; et al
- Address
- Department of Pathology, National Defense Medical College, Saitama, Japan.
- Source
- Nephron, 1992, 60:4, 436-42
- Abstract
- A 55-year-old woman was admitted to our hospital, complaining of general malaise,
muscular weakness, anorexia and weight loss. She had a history of ingesting of a certain
germanium (Ge) compound over the preceding 19 months, with a total dose of 47 g as Ge
element. She was found to have renal failure (blood urea nitrogen, 44 mg/dl; serum
creatinine, 2.6 mg/dl) without abnormal findings in urinalysis, and muscular and nervous
damage. Initially, polymyositis was diagnosed and prednisolone administered. However, no
improvement was seen, and neuromuscular symptoms and signs steadily worsened, ending in
death. Microscopic study of the kidney showed that lipofuscin granules increased in the
cells of the thick ascending limb of Henle's loop to the distal convoluted tubule
accompanying mild tubular atrophy and that some of the tubules of these segments had
vacuolar degeneration or desquamation. No apparent glomerular and vascular changes were
observed. High Ge content was found in serum, urine and various tissues, e.g., spleen,
liver, kidney, adrenal gland and myocardium, while in controls Ge could not be detected in
sera, urine or tissues. We also review case reports about Ge toxicity, and discuss the
pathogenesis of renal failure induced by Ge compounds.
- Language of Publication
- English
- Unique Identifier
- 92261746
- MeSH Heading (Major)
- Germanium|AD/*TO; Kidney|*DE/PA
- MeSH Heading
- Case Report; Female; Human; Kidney Failure, Acute|CI/PA; Middle Age; Muscles|DE; Nervous
System|DE
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW OF REPORTED CASES
- ISSN
- 0028-2766
- Country of Publication
- SWITZERLAND
- CAS Registry/EC Number
- 7440-56-4 (Germanium)
Record 23 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Spirogermanium: a new investigational drug of novel structure and lack of bone marrow
toxicity.
- Author
- Slavik M; Blanc O; Davis J
- Address
-
- Source
- Invest New Drugs, 1983, 1:3, 225-34
- Abstract
- Spirogermanium (NSC 192965) is a new metallic investigational anticancer drug of novel
heterocyclic structure. Although its mode of action has not been fully elucidated, it
appears that spirogermanium is not a phase or cell cycle specific drug and inhibits DNA,
RNA and protein synthesis, the protein synthesis being the most susceptible to this agent.
Spirogermanium has shown cytotoxic activity in vitro against several human tumor cell
lines at concentrations (1 micrograms/ml) that were also found toxic to the cultured rat
neurons. Although spirogermanium has no effect on normal bone marrow colony forming cells
in mice, dogs, or man, it has revealed cytotoxic activity in vitro against human myeloid
leukemia cell line K 562 at clinically achievable concentrations. These in vitro findings,
indicating selective cytotoxic activity against leukemic cells suggest this drug as a
candidate for clinical studies in acute and chronic leukemias. Spirogermanium has revealed
activity in vivo against intraperitoneally implanted Walker 256 sarcoma, 13762 mammary
adenocarcinoma, and 11095 prostatic carcinoma in rats, but no antitumor activity in vivo
was found in the murine tumors used in the past by the NCI screen (L 1210 and P 388
leukemia, B 16 melanoma, Lewis lung carcinoma). Spirogermanium is remarkable for its lack
of bone marrow toxicity confirmed in preclinical toxicology and clinical studies;
moderate, predictable, and reversible CNS toxicity is dose-limiting. Activity in malignant
lymphoma, ovarian cancer, breast cancer, large bowel cancer, and prostatic cancer was
reported in the clinical studies. The drug is currently under clinical investigation
against the wide spectrum of solid tumors and malignant lymphomas. The dose of 80-120
mg/m2, given by 60' infusion three times a week, is currently used and tolerated in Phase
II clinical studies. The recently introduced five days continuous infusion schedule has
been also under clinical investigation and the doses of 250-300 mg/m2/day are recommended
for Phase II studies. Of interest are results reported in this paper of spirogermanium in
vitro preferential activity against the resistant strains of Plasmodium falciparum at
clinically achievable concentrations suggesting this drug as a possible new antimalarial
agent of novel structure.
- Language of Publication
- English
- Unique Identifier
- 84288335
- MeSH Heading (Major)
- Antineoplastic Agents|AE/*PD/TU; Bone Marrow|*DE; Germanium|*PD/TO/TU; Spiro
Compounds|*PD/TO/TU
- MeSH Heading
- Animal; Chemistry; Dogs; Drug Evaluation; Human; Mice; Neoplasms|DT; Neoplasms,
Experimental|DT; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0167-6997
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4
(Germanium)
Record 24 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Phase I study of spirogermanium given daily.
- Author
- Legha SS; Ajani JA; Bodey GP
- Address
-
- Source
- J Clin Oncol, 1983 May, 1:5, 331-6
- Abstract
- Spirogermanium, an azaspirane compound, has recently had limited clinical trials using a
schedule of intravenous injection one to three times every week. The observation of
clinical antitumor activity and lack of myelosuppression prompted us to investigate
further the clinical effects of spirogermanium administered on various schedules. A total
of 52 patients with advanced metastatic tumors refractory to standard therapy were treated
with spirogermanium. Three different schedules of drug administration were evaluated.
Initially, a short daily IV infusion for 5 days every week was evaluated, starting with a
dose of 30 mg/m2/day. A total of 22 patients received 69 courses with a dose range of
30-120 mg/m2/day for 5 days every week. The maximum tolerated dose was 100 mg/m2/day IV
over 1 hr and 120 mg/m2 over 2-3 hr. In the second phase of the study, 12 patients
received 41 courses of spirogermanium as a 24-hr continuous infusion for 5 days/wk at a
dose of 150-375 mg/m2/day. The maximum tolerated dose was 200 mg/m2/day for 5 days. In the
third phase of the study, 18 patients received spirogermanium as a continuous infusion
daily for a median of 30 days (range 6-77 days) in a dose range of 100-200 mg/m2/day. The
maximum tolerated dose was 150 mg/m2/day. Of the 44 assessable patients, 3 demonstrated a
partial response and 3 had minor tumor regression; all responses occurred in lymphoma
patients. The dose-limiting toxicity of spirogermanium was neurologic; other side effects
consisted of mild anorexia, nausea and vomiting, and possible lung toxicity. There was no
clear evidence of cumulative toxicity despite daily administration of spirogermanium. Our
data suggest that spirogermanium can be administered daily by several different schedules,
and the optimum dose depends on the infusion time and the duration of therapy. The
delivery of drug by continuous infusion permitted administration of twofold higher dose
levels compared to the standard IV schedules used in previous studies.
- Language of Publication
- English
- Unique Identifier
- 84137813
- MeSH Heading (Major)
- Colonic Neoplasms|*DT; Germanium|*AD/AE; Lymphoma|*DT; Ovarian Neoplasms|*DT; Spiro
Compounds|*AD/AE
- MeSH Heading
- Adult; Aged; Comparative Study; Dose-Response Relationship, Drug; Drug Administration
Schedule; Drug Evaluation; Female; Human; Infusions, Parenteral; Male; Middle Age;
Nausea|CI; Nervous System Diseases|CI
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0732-183X
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)
Record 25 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Nephrotoxicity and neurotoxicity in humans from organogermanium compounds and germanium
dioxide.
- Author
- Schauss AG
- Address
- Life Sciences Division, American Institute for Biosocial Research, Inc., Tacoma, WA
98401.
- Source
- Biol Trace Elem Res, 1991 Jun, 29:3, 267-80
- Abstract
- There is no known biological requirement for germanium (Ge), germanates, or any
organogermanium compound. Ge deficiency has not been demonstrated in any animal. The
estimated average dietary intake of Ge in humans is 1.5 mg/d. Ge is widely distributed in
edible foods, all of which, with few exceptions, contain less than 5 ppm Ge, since higher
levels are toxic to most plants. Ingestion of Ge compounds has been shown to produce toxic
effects in experimental animals. In recent years inorganic germanium salts and novel
organogermanium compounds, such as carboxyethyl germanium sesquioxide (Ge-132) and
lactate-citrate-germanate (Ge lactate citrate) have been sold as "nutritional
supplements" in some countries for their purported immunomodulatory effects or as
health-producing elixirs, resulting in intakes of Ge significantly exceeding the estimated
average dietary intake. Since 1982, there have been 18 reported cases of acute renal
dysfunction or failure, including two deaths, linked to oral intake of Ge elixirs
containing germanium dioxide (GeO2) or Ge-132. In these cases, biopsies show vacuolar
degeneration in renal tubular epithelial cells, without proteinuria or hematuria, in the
absence of glomerular changes. Serum creatinine levels have been well above 400 mumol/L in
such patients. In 17 of 18 cases, accumulated elemental Ge intakes reportedly ranged
between 16 to 328 g over a 4-36 mo period, or between 100 to 2000 times the average
estimated dietary intake for human. In surviving patients, renal function improved after
discontinuation of Ge supplementation. However, in no case was recovery complete. One
organogermanium compound, an azaspiran organogermanium compound, 2-aza-8-germanspiro[4,5]
decane-2-propamine-8,8-diethyl-N,N-dimethyl dichloride (spirogermanium), has been found to
cause both neurotoxicity and pulmonary toxicity in phase I and II studies examining its
chemotherapeutic potential as an antitumor drug in the treatment of various malignancies.
In cancer patients given the drug spirogermanium, 40% experienced marked, yet transient
neurotoxicity. Two patients suffered from pulmonary toxicity. Results of phases I and II
human cancer trials for spirogermanium have not been favorable, with the exception of
moderate benefits for three types of malignancies. It is recommended that patients exposed
to long-term (greater than 3 mo) Ge supplementation at levels well above the estimated
daily intake be medically supervised and monitored for potential renal-, pulmonary- or
neurotoxicity. Further study regarding the mechanism of Ge-induced nephrotoxicity in human
is warranted.
- Language of Publication
- English
- Unique Identifier
- 92304696
- MeSH Heading (Major)
- Germanium|*TO; Kidney|DE/*PA; Nervous System|DE/*PA; Organometallic Compounds|*TO
- MeSH Heading
- Animal; Creatinine|BL; Human; Kidney Function Tests; Kidney Tubules|DE/PA; Lethal Dose
50; Mice
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0163-4984
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Organometallic Compounds); 1310-53-8 (germanium oxide); 60-27-5 (Creatinine);
7440-56-4 (Germanium)
Record 26 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Identification of 241Am in the axillary lymph nodes with an intrinsic germanium
detector.
- Author
- Graham SG; Kirkham SJ
- Address
-
- Source
- Health Phys, 1983, 44 Suppl 1:, 343-52
- Abstract
- A routine measurement with two 200 mm-diameter phoswich detectors, placed one each side
of the sternum, yielded an apparent lung content of 17 nCi 241Am for a subject. subject.
Inspection of the data revealed that there were many more counts from the left side than
from the right and that there was a greater number of Np L X rays observed, relative to
the L gamma ray, than would be expected for a uniform lung distribution of 241Am. These
observations suggested a shallow localised deposit in the left side of the chest. The
subject's working history could not rule out an inhalation exposure, but he was known to
have had a wound contaminated with Pu/Am in his left hand 16 yr previously. The wound had
contained approx. 0.02-0.03 mu Ci 241Am initially, most of which was excised from the
wound site after 50 days. Prompted by this knowledge we used a 50mm-diameter intrinsic Ge
detector to examine the wound and relevant lymph node sites. The results demonstrated a
localised deposit of 241Am in the axillary lymph nodes with approx. 1 nCi 241Am at the
wound site. Subsequent measurements made with the phoswich detectors suggested that there
was approx. 7 nCi 241Am in the lymph nodes with approx. 1 nCi 241Am in the liver, thereby
accounting for most of the detectable 241Am contamination in the thorax.
- Language of Publication
- English
- Unique Identifier
- 83237611
- MeSH Heading (Major)
- Americium|*AN; Germanium|*AN; Lymph Nodes|*AN; Radioisotopes|*AN
- MeSH Heading
- Axilla; Calibration; Case Report; Human; Male; Occupational Diseases|DI; Radiation
Injuries|DI; Time Factors
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0017-9078
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Radioisotopes); 7440-35-9 (Americium); 7440-56-4 (Germanium)
Record 27 from database: MEDLINE
Return To Menu Choice #20
- Title
- Performance of an array of large-volume germanium detectors for whole-body counting.
- Author
- Palmer HE; Rieksts GA; Lynch TP
- Address
- Pacific Northwest Laboratory, Richland, WA 99352.
- Source
- Health Phys, 1991 Nov, 61:5, 595-600
- Abstract
- An array of four large-volume coaxial germanium detectors was installed in a shielded
room for the in vivo measurement of gamma emitters in the body. All four detectors are in
a single 50-L dewar of liquid nitrogen and are positioned underneath the supine subject
with the axes of the detector elements parallel with the length of the body. This
orientation gives approximately 15% more counting efficiency than having the axes of the
detectors perpendicular to the body length. The detectors have resolutions that are less
than 2 keV with an average of 1.86 keV for the 60Co 1.33-MeV gamma-ray peak. The
efficiencies of the four detectors range from 59% to 77% of a 7.62- x 7.62-cm (3- x 3-in.)
NaI (Tl) detector. The detectors are interfaced to a multichannel analyzer such that
spectra from the detectors are stored both as a sum of all counts from the four detectors
and as a spectrum from each detector. The sensitivity of the germanium array for measuring
radioactivity in the body exceeds that of multiple large NaI (Tl) detectors for measuring
single radionuclides in the body and is much superior for measuring internal depositions
of radionuclide mixtures. Another major advantage of this system compared to NaI(Tl)
systems is that the results can be calculated by computer analysis with minimal human
interpretation. The sensitivity of the array configuration is described and applications
of the array in other configurations, such as that used for measuring the very small
quantities of 24Na induced in the body during air travel, are also discussed.
- Language of Publication
- English
- Unique Identifier
- 92091145
- MeSH Heading (Major)
- Germanium|*; Whole-Body Counting|*IS
- MeSH Heading
- Bismuth|AN; Comparative Study; Human; Lead|AN; Polonium|AN; Radioisotopes|AN;
Scintillation Counting; Support, U.S. Gov't, Non-P.H.S.
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0017-9078
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Radioisotopes); 0 (Radon Daughters); 7439-92-1 (Lead); 7440-08-6 (Polonium);
7440-56-4 (Germanium); 7440-69-9 (Bismuth)
Record 28 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Germanium poisoning: clinical symptoms and renal damage caused by long-term intake of
germanium.
- Author
- Obara K; Saito T; Sato H; Yamakage K; Watanabe T; Kakizawa M; Tsukamoto T; Kobayashi K;
Hongo M; Yoshinaga K
- Address
- Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai,
Japan.
- Source
- Jpn J Med, 1991 Jan-Feb, 30:1, 67-72
- Abstract
- We report five patients who have taken inorganic germanium preparations over a prolonged
period. In all cases, the renal function deteriorated with no proteinuria or hematuria.
Histological examination of the kidneys showed widespread tubular degeneration and
interstitial fibrosis with minor glomerular abnormalities. Most patients had
gastrointestinal symptoms such as vomiting, anorexia and weight loss; one patient had
peripheral neuropathy and myopathy. A considerable amount of germanium was detected in the
hair or nails of these patients. These cases clearly show that abuse of inorganic
germanium compounds can induce renal damage with various extrarenal manifestations.
- Language of Publication
- English
- Unique Identifier
- 91325443
- MeSH Heading (Major)
- Drugs, Non-Prescription|*PO; Gastrointestinal Diseases|*CI; Germanium|AD/AN/*PO; Kidney
Diseases|*CI; Peripheral Nervous System Diseases|*CI
- MeSH Heading
- Aged; Anemia|CI; Case Report; Child; Fatigue|CI; Female; Hair|CH; Human; Male; Mental
Retardation|DT; Middle Age; Nails|CH; Support, Non-U.S. Gov't
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0021-5120
- Country of Publication
- JAPAN
- CAS Registry/EC Number
- 0 (Drugs, Non-Prescription); 7440-56-4 (Germanium)
Record 29 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Nephrotoxicity in humans by the ultratrace element germanium.
- Author
- Schauss AG
- Address
- Life Sciences Division, American Institute for Biosocial Research, Inc., Tacoma,
Washington 98401.
- Source
- Ren Fail, 1991, 13:1, 1-4
- Abstract
- Acute renal failure (ARF) or renal dysfunction (RD) associated with germanium-induced
nephrotoxicity has been reported in 18 patients since 1982. In 2 of these cases the
patients died of acute renal and cardiogenic failure. In 17 of 18 cases biopsies showed
vacuolar degeneration in renal tubular epithelial cells in the absence of glomerular
changes, without proteinuria or hematuria. Accumulated elemental Ge intake in 17 patients
over a period of 4 to 36 months ranged between 16 and 328 g, or more than 100 to 2000
times the average estimated dietary intake of Ge for man (1.5 mg/d; range 0.40 to 3.40
mg/d). The biological half-life of Ge is 4.5 days for kidneys, the highest retention level
of any organ. The mean concentration of Ge in healthy adult kidneys is 9.0 mg/kg wet
weight. In 3 patients studied with Ge-induced RD or ARF, urinary Ge excretion was 9, 15,
and 60 ng/mL, compared to greater than 5 ng/mL in healthy controls, and remained elevated
even 12 months after discontinuing supplemental Ge intake. The mechanism for Ge-induced
nephrotoxicity remains unknown, although the suspected cause is the inorganic Ge salts,
such as germanium dioxide. Sufficient evidence for a role of organogermanium compounds,
such as carboxyethyl germanium sesquioxide or citrate-lactate germanate, in Ge-induced
nephrotoxicity remains lacking. The recent introduction of over-the-counter Ge
"nutritional" supplements in some countries increases the risk of additional
cases of Ge-induced nephrotoxicity, especially if appreciable levels of inorganic Ge salts
are present and consumed for long periods (greater than 3 months) at levels above the
average daily estimated dietary intake for Ge.(ABSTRACT TRUNCATED AT 250 WORDS)
- Language of Publication
- English
- Unique Identifier
- 92021635
- MeSH Heading (Major)
- Germanium|AD/*AE/ME; Kidney Failure, Acute|*CI
- MeSH Heading
- Animal; Diet; Dose-Response Relationship, Drug; Half-Life; Human; Kidney|ME
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0886-022X
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 7440-56-4 (Germanium)
Record 30 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Cytotoxic effects and biological activity of
2-aza-8-germanspiro[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC
192965; spirogermanium) in vitro.
- Author
- Hill BT; Whatley SA; Bellamy AS; Jenkins LY; Whelan RD
- Address
-
- Source
- Cancer Res, 1982 Jul, 42:7, 2852-6
- Abstract
- Lethal and other biological effects of
2-aza-8-germanspiro[4,5]decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC
192965; spirogermanium), representing a new chemical class of compound exhibiting
antitumor activity, have been studied in vitro. Survival curves for NIL 8 hamster cells
were exponential with greater kill occurring with increasing drug concentrations and
longer exposure times. Cytotoxicity was temperature dependent. "Quiescent"
cultures were significantly less sensitive to spirogermanium than were logarithmically
growing cells. These lethal effects showed no phase specificity. There was no evidence of
progression delay through the cycle following spirogermanium treatment. When
spirogermanium was tested against a range of human cell lines, the consistency of the
values for the drug concentration required to reduce survival by 50% on the exponential
part of the survival curve, derived from colony-forming assays, was most marked. The
survival curves, characterized by an initial shoulder, were steep and exponential with
measurements possible over only a narrow concentration range since complete cell lysis
occurred at levels causing a greater than 2-log kill. Cell membrane damage by
spirogermanium, as judged by dye exclusion, was progressive with time and increasing drug
concentrations. Protein synthesis proved most susceptible to the drug. Spirogermanium
concentrations cytotoxic to tumor cells were also toxic to cultured rat neurons,
confirming the clinical neurological toxicity encountered. The precise mode of action of
spirogermanium remains to be established, and these data further illustrate its apparent
lack of specificity.
- Language of Publication
- English
- Unique Identifier
- 82208265
- MeSH Heading (Major)
- Antineoplastic Agents|*PD; Germanium|*PD; Spiro Compounds|*PD
- MeSH Heading
- Animal; Carcinoma, Squamous Cell|PA; Cell Cycle|DE; Cell Line; Cell Survival|DE; Cells,
Cultured; Colonic Neoplasms|PA; Female; Hamsters; Human; Mesocricetus; Neuroblastoma|PA;
Neurons|DE; Ovary|DE; Rats
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0008-5472
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4
(Germanium)
Record 31 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Determination of germanium and some other elements in hair, nail, and toenail from
persons exposed and unexposed to germanium.
- Author
- Morita H; Shimomura S; Okagawa K; Saito S; Sakigawa C; Sato H
- Address
-
- Source
- Sci Total Environ, 1986 Dec 31, 58:3, 237-42
- Abstract
- Inductively coupled atomic emission spectrometry was used for the determination of
germanium in hair, nail, and toenail. The levels of germanium in three individuals
administered a high concentration of a germanium preparation daily for about 12-16 months
were very high: 56.4-173.7; 5.4-35.0; and 14.0-15.8 micrograms g-1 in hair, nail, and
toenail, respectively. The levels for normal or unexposed persons are very low and were
not detected by the method.
- Language of Publication
- English
- Unique Identifier
- 87148999
- MeSH Heading (Major)
- Environmental Exposure|*; Germanium|*AN; Hair|*AN; Nails|*AN
- MeSH Heading
- Adult; Comparative Study; Female; Foot; Hand; Human; Kidney Diseases|ME; Male; Muscular
Diseases|ME; Reference Values; Spectrum Analysis
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0048-9697
- Country of Publication
- NETHERLANDS
- CAS Registry/EC Number
- 7440-56-4 (Germanium)
Record 32 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Rotating laminar emission camera with GE-detector: an analysis.
- Author
- Mauderli W; Fitzgerald LT; Urie MM; Tosswill H
- Address
-
- Source
- Med Phys, 1981 Nov-Dec, 8:6, 871-6
- Abstract
- Design criteria for a germanium detector emission camera with laminar
collimator-detector geometry are reported. In this design, parallel plates above a grooved
germanium slab form detector channels which accumulate data in multiple projections
through 180 degrees. Activity distribution is determined through mathematical
reconstruction from the projections. The laminar design has greater efficiency than a
hole-collimated device due to a favorable open area ratio and due to collimation in only
one dimension. The relative sensitivity at the center of the detector strip increases with
detector length and distance from collimator face. Spatial resolution depends upon the
design geometry (septal penetration and scatter within the crystal are of such small
magnitude that degradation of the point spread function is minimal). A 30 channel protype
device (ROLEC) shows good correlation with theoretically determined PSF and
signal-to-noise ratio (SNR). Measuring times projected for a clinical sized device (300 mm
diam) are about 4.6 times that of the Anger camera (with same SNR) and high resolution
collimator.
- Language of Publication
- English
- Unique Identifier
- 82103582
- MeSH Heading (Major)
- Germanium|*; Radionuclide Imaging|*IS
- MeSH Heading
- Human
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0094-2405
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 7440-56-4 (Germanium)
Record 33 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Rotating laminar emission camera with GE-detector: experimental results.
- Author
- Urie MM; Mauderli W; Fitzgerald LT; Williams CM; Tosswill CH
- Address
-
- Source
- Med Phys, 1981 Nov-Dec, 8:6, 865-70
- Abstract
- Experimental results of a prototype rotating laminar emission camera (ROLEC) for nuclear
medicine imaging are reported. A 11.5 mm thick, 45 x 45 mm high-purity germanium detector
is segmented into 30 1.47 mm wide parallel channels and collimated with 39 mm high
parallel plates. Projection data acquired at multiple angular orientations as the
detector-collimator assembly is rotated about its center are mathematically reconstructed
to image the activity distribution. The spatial resolution of the ROLEC is at least twice
as good, at all distances, as that of gamma cameras with high resolution collimators. The
better energy resolution of the germanium enhances the detection and resolution of the
ROLEC in comparison to gamma cameras with NaI(T1) crystals, the relative superiority
increasing with greater volumes and with greater depths. Adequate sensitivity is
maintained while achieving these improvements in spatial resolution and in practice; ROLEC
images are acquired in less time than pinhole collimator images with gamma cameras.
- Language of Publication
- English
- Unique Identifier
- 82103581
- MeSH Heading (Major)
- Germanium|*; Radionuclide Imaging|*IS
- MeSH Heading
- Animal; Human; Rats
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0094-2405
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 7440-56-4 (Germanium)
Record 34 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Cerebral distribution of 133-Xe and blood flow measured with high purity germanium.
- Author
- Reich T; Rusinek H; Youdin M; Clagnaz M
- Address
-
- Source
- Stroke, 1985 Jan-Feb, 16:1, 92-101
- Abstract
- Distribution of cerebral blood flow was measured with an array of 200 ultra-pure
germanium radiation detectors and 133-Xe by inhalation. The array "sees" the
head as a composite of different subvolumes and enables measurement of the concentration
history of tracer every 1-10 sec in each subvolume simultaneously. Subvolume mean flows,
(fm), and partition coefficients, lambda m, are derived by compartmental analysis of
tissue concentration washout curves. Errors from "cross talk," scalp radiation,
"look through," and assumed partition coefficients are eliminated. Average fm
adjusted for 40 mm Hg PACO2 in 14 cortical subvolumes (7 right, 7 left) of four normal
21-24 year old controls ranged from 50 to 60 ml/100 cc tissue/min, and lambda m ranged
from 0.97 to 1.14. Average fm and lambda m in white matter was 24 ml/100 cc/min and 1.42 -
1.14 respectively. During CO2 inhalation, right and left hemispheric fm increased 6.4% and
5.7%/mm Hg respectively, whereas white matter fm increased 2.2% and 3.4% mm Hg
respectively. There was no systematic difference between front and back or dominant vs
non-dominant sides. Three 73-84 year old controls had reduced fm and CO2 reactivity in all
subvolumes, lambda m was in the same range as in younger controls. Two patients with
intracranial cerebrovascular disease showed excellent localization of ischemic subvolumes.
One patient with asymptomatic unilateral 98% stenosis of the internal carotid artery had a
similar distribution of blood flow in both hemispheres.
- Language of Publication
- English
- Unique Identifier
- 85091359
- MeSH Heading (Major)
- Cerebrovascular Circulation|*; Cerebrovascular Disorders|*PP/RI; Germanium|*DU; Xenon
Radioisotopes|*DU
- MeSH Heading
- Adult; Aged; Carbon Dioxide; Female; Human; Male; Partial Pressure; Support, Non-U.S.
Gov't; Tomography, Emission-Computed|IS/MT
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0039-2499
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Xenon Radioisotopes); 124-38-9 (Carbon Dioxide); 7440-56-4 (Germanium)
Record 35 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- A phase II study of spirogermanium in advanced human malignancy.
- Author
- Vogelzang NJ; Gesme DH; Kennedy BJ
- Address
-
- Source
- Am J Clin Oncol, 1985 Aug, 8:4, 341-4
- Abstract
- Spirogermanium, a heavy metal compound in which germanium has been substituted in an
azaspirane ring structure, was studied in 39 patients with advanced malignant neoplasms.
Thirty-one patients were considered evaluable for toxic effects of spirogermanium.
Transient neurological symptoms occurred in 12 patients (39%), including dizziness or
lightheadedness, marked fatigue, visual blurring, ataxia, paresthesia, and nausea. These
symptoms could be reduced by infusing the drug over 2 hours rather than over 1 hour.
Persistent neurotoxicity in the form of partial loss of taste or extreme weakness was
observed in three patients. No evidence of hematologic, renal, or hepatic toxicity was
observed. Antitumor activity of spirogermanium was not identified in this group of heavily
pretreated patients. Spirogermanium had limited and acceptable toxicity in utilizing a
dose of 120 mg/m2 infused over 2 hours, three times weekly.
- Language of Publication
- English
- Unique Identifier
- 86100364
- MeSH Heading (Major)
- Germanium|AD/AE/*TU; Neoplasms|*DT; Spiro Compounds|AD/AE/*TU
- MeSH Heading
- Adult; Aged; Clinical Trials; Drug Administration Schedule; Drug Evaluation; Female;
Half-Life; Human; Infusions, Parenteral; Kinetics; Male; Middle Age
- Publication Type
- CLINICAL TRIAL; JOURNAL ARTICLE
- ISSN
- 0277-3732
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)
Record 36 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Accumulation of germanium in the tissues of a long-term user of germanium preparation
died of acute renal failure.
- Author
- Nagata N; Yoneyama T; Yanagida K; Ushio K; Yanagihara S; Matsubara O; Eishi Y
- Address
-
- Source
- J Toxicol Sci, 1985 Nov, 10:4, 333-41
- Abstract
- Acute renal failure developed in a patient accompanied by systemic manifestations such
as myopathy and skin rash. The patient, a middle aged house wife, had been taking 600 mg
of germanium (Ge) preparation daily for 18 months as an elixir. The main component of the
preparation was GeO2 and some organic compound was also present. Histological study of the
kidney post mortem showed foamy cell transformation of glomerular epithelia, degeneration
of tubular epithelia with red blood cell casts and urate crystals, and a mild
proliferation of mesangial matrix. Analysis of the tissue content of Ge, prompted by her
history, revealed an increased accumulation of the metal. As compared to a non-user died
of liver cirrhosis, the concentration of the metal was higher particularly in the spleen
(183X), thyroid gland (175X), psoas muscle (93X), jejunum (76X), and renal cortex (69X).
So far, neither accumulation of Ge in humal tissue nor systemic toxicity of the Ge in
human has been reported. The relevance of massive accumulation of Ge to the renal failure
as well as to other systemic manifestations the patient presented remains to be clarified.
- Language of Publication
- English
- Unique Identifier
- 86171879
- MeSH Heading (Major)
- Germanium|AD/AE/*ME; Kidney Failure, Acute|*CI/PA
- MeSH Heading
- Case Report; Female; Human; Kidney|PA; Tissue Distribution
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0388-1350
- Country of Publication
- JAPAN
- CAS Registry/EC Number
- 7440-56-4 (Germanium)
Record 37 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- A phase II study of spirogermanium as second line therapy in patients with poor
prognosis lymphoma. An NCI Canada Clinical Trials Group Study.
- Author
- Eisenhauer E; Quirt I; Connors JM; Maroun J; Skillings J
- Address
-
- Source
- Invest New Drugs, 1985, 3:3, 307-10
- Abstract
- The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study
of spirogermanium given daily for 5 days every 3 weeks to patients with poor prognosis
non-Hodgkin's lymphomas. All patients had had a maximum of one prior treatment regimen. No
responses were seen in 13 evaluable patients. Toxicity was primarily neurologic and mild
or moderate in most patients. There is no evidence of activity of spirogermanium given in
this schedule in this subset of lymphoma patients.
- Language of Publication
- English
- Unique Identifier
- 86058482
- MeSH Heading (Major)
- Antineoplastic Agents|AE/*TU; Germanium|AE/*TU; Lymphoma|*DT; Spiro Compounds|AE/*TU
- MeSH Heading
- Aged; Drug Evaluation; Human; Middle Age; Nervous System Diseases|CI; Prognosis
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0167-6997
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4
(Germanium)
Record 38 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- A phase II study of spirogermanium in patients with metastatic malignant melanoma. An
NCI Canada Clinical Trials Group Study.
- Author
- Eisenhauer E; Kerr I; Bodurtha A; Iscoe N; McCulloch P; Pritchard K; Quirt I
- Address
-
- Source
- Invest New Drugs, 1985, 3:3, 303-5
- Abstract
- The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study
of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients
with malignant melanoma. In 21 evaluable patients one complete response was seen (response
rate 5%). Disease progression occurred in the other 20 patients. Toxicity was primarily
neurologic and mild or moderate in most patients, though there was one treatment related
death. In this schedule spirogermanium has extremely limited activity against malignant
melanoma and will not contribute significantly to the systemic therapy of this disease.
- Language of Publication
- English
- Unique Identifier
- 86058481
- MeSH Heading (Major)
- Antineoplastic Agents|AE/*TU; Germanium|AE/*TU; Melanoma|*DT/PA; Spiro Compounds|AE/*TU
- MeSH Heading
- Adult; Aged; Drug Evaluation; Female; Human; Male; Middle Age; Neoplasm Metastasis
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0167-6997
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4
(Germanium)
Record 39 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
- Title
- Germanium dioxide-induced nephropathy: a new type of renal disease.
- Author
- Sanai T; Okuda S; Onoyama K; Oochi N; Oh Y; Kobayashi K; Shimamatsu K; Fujimi S;
Fujishima M
- Address
- Second Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka,
Japan.
- Source
- Nephron, 1990, 54:1, 53-60
- Abstract
- Chronic renal failure developed in 5 patients who were taking germanium dioxide
(GeO2)-containing compounds. Renal functional deterioration was slow but progressive and
dialysis treatment was necessitated temporarily in 2 patients. After the discontinuation
of GeO2, the impaired renal function tended to improve but remained abnormal for an
observation period of 10-40 months. The lack of proteinuria and hematuria was
characterized as the clinical manifestations. Renal biopsy specimens revealed the tubular
epithelial cell degeneration containing hematoxylin-positive fine granules on light
microscopy, and electron-dense inclusions in the swollen mitochondria on electron
microscopy. These findings localized mainly in distal segment of the tubules. In the rats
given GeO2 orally for 10 weeks, similar histological lesions were evident, as manifested
by marked weight loss, anemia, azotemia, and negative proteinuria. In the rats given
carboxyethylgermanium sesquioxide, these changes were not observed and Ge concentration of
kidney was significantly lower than in the rats given GeO2. The present study indicates
that chronic GeO2 intake causes progressive renal dysfunction characterized by the
degeneration of distal tubules.
- Language of Publication
- English
- Unique Identifier
- 90114564
- MeSH Heading (Major)
- Germanium|*AE/TO; Kidney Failure, Chronic|*CI/PA
- MeSH Heading
- Adolescence; Adult; Animal; Case Report; Female; Human; Male; Middle Age; Rats; Rats,
Inbred Strains; Support, Non-U.S. Gov't
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0028-2766
- Country of Publication
- SWITZERLAND
- CAS Registry/EC Number
- 1310-53-8 (germanium oxide); 7440-56-4 (Germanium)